Lawrence A. Kenyon
Chief Financial Officer, Director · Outlook Therapeutics, Inc.
- 2026
- Aug 14, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Lawrence A. Kenyon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ghiath M. Sukhtian - $7.50M in OTLK purchases and sales in the last 12 months
- Kurt J. Hilzinger - $177K in OTLK purchases and sales in the last 12 months
- Faisal Ghiath Sukhtian - $150K in OTLK purchases and sales in the last 12 months
- Yezan Munther Haddadin - $39K in OTLK purchases and sales in the last 12 months
- Randy H. Thurman - $2K in OTLK purchases and sales in the last 12 months
- Robert Charles Jahr - OTLK
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Lawrence A. Kenyon?
Lawrence A. Kenyon is a corporate insider, tracked as Chief Financial Officer, Director of Outlook Therapeutics, Inc. (OTLK). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Lawrence A. Kenyon submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Lawrence A. Kenyon been buying or selling stock?
Recorded transactions: 2 open-market purchases and 0 open-market sales across all tracked filings.
